Myatorlip (Atorvastatin, Ezetimibe)

Atorvastatin reduces cholesterol synthesis in the liver by inhibiting HMG‑CoA reductase, while ezetimibe blocks the intestinal NPC1L1 transporter, decreasing absorption of dietary and biliary cholesterol. Together they provide a complementary reduction of total and LDL cholesterol.

The specific dose of Myatorlip is determined by the prescribing healthcare professional based on the individual’s lipid profile, medical history, and treatment goals. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

The safety of Myatorlip in pregnancy and lactation has not been established. It should be avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under close medical supervision.

To order Myatorlip, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myatorlip offers a fixed‑dose combination of a statin and a cholesterol absorption inhibitor, providing greater LDL‑cholesterol reduction than either component alone. Compared with monotherapy, the combination can achieve target lipid levels with a single tablet, potentially improving adherence.

Myatorlip tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and light, and keep out of reach of children.

Myatorlip is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious adverse effects include rhabdomyolysis (muscle breakdown), severe liver injury, and hypersensitivity reactions such as rash or angioedema. Patients should promptly report unexplained muscle pain, weakness, dark urine, or signs of liver dysfunction such as jaundice.

Myatorlip is contraindicated in individuals with active liver disease, unexplained persistent elevations of hepatic enzymes, known hypersensitivity to atorvastatin, ezetimibe, or any excipients, and in patients taking contraindicated medications such as strong CYP3A4 inhibitors.